The New Bisphosphonate, Zometa®(Zoledronic Acid), Decreases Skeletal Complications in Both Osteolytic and Osteoblastic Lesions: A Comparison to Pamidronate
- 1 January 2002
- journal article
- research article
- Published by Taylor & Francis in Cancer Investigation
- Vol. 20 (sup2) , 45-54
- https://doi.org/10.1081/cnv-120014886
Abstract
Bisphosphonates are the treatment of choice for lytic bone lesions associated with breast cancer. In contrast, bone lesions associated with prostate cancer are predominately osteoblastic. Zoledonic...Keywords
This publication has 42 references indexed in Scilit:
- METABOLIC BONE DISEASE INDUCED BY PROSTATE CANCER: RATIONALE FOR THE USE OF BISPHOSPHONATESJournal of Urology, 2001
- INCIDENCE OF SKELETAL COMPLICATIONS IN PATIENTS WITH BONE METASTATIC PROSTATE CANCER AND HORMONE REFRACTORY DISEASE: PREDICTIVE ROLE OF BONE RESORPTION AND FORMATION MARKERS EVALUATED AT BASELINEJournal of Urology, 2000
- Stimulation of Bone Formation in Vitro and in Rodents by StatinsScience, 1999
- Systemic Administration of Acidic Fibroblast Growth Factor (FGF-1) Prevents Bone Loss and Increases New Bone Formation in Ovariectomized RatsJournal of Bone and Mineral Research, 1999
- Global cancer statisticsCA: A Cancer Journal for Clinicians, 1999
- BisphosphonatesEuropean Journal Of Cancer, 1998
- Skeletal complications of malignancyCancer, 1997
- Mechanisms of bone metastasisCancer, 1997
- In VivoStimulation of Endosteal Bone Formation by Basic Fibroblast Growth Factor in RatsGrowth Factors, 1993
- Spread of prostatic cancer to boneUrology, 1983